Oncologic Outcome and Distant Metastasis of Head and Neck Adenoid Cystic Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤희수 | - |
dc.contributor.author | 박상규 | - |
dc.contributor.author | 박혜진 | - |
dc.contributor.author | 송창면 | - |
dc.contributor.author | 지용배 | - |
dc.contributor.author | 태경 | - |
dc.date.accessioned | 2022-07-10T20:51:13Z | - |
dc.date.available | 2022-07-10T20:51:13Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2018-12 | - |
dc.identifier.issn | 1229-5183 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/148720 | - |
dc.description.abstract | Background/Objectives Adenoid cystic carcinoma is the second most common salivary carcinoma. It occurs commonly in the submandibular gland, sublingual gland and minor salivary gland. Local recurrence and distant metastasis are the leading cause of death. The aim of this study was to evaluate long-term oncologic outcomes of patients with head and neck adenoid cystic carcinoma focusing on distant metastasis. Materials & Methods We retrospectively studied 39 patients who were diagnosed with and treated for adenoid cystic carcinoma of the head and neck from December 1996 to May 2018. The clinicopathologic characteristics of patients such as age, sex, primary site and TNM stage, and treatment methods, recurrence and distant metastasis after treatment, survival rate, and treatment method for recurrence were analyzed. Results Of 39 patients, 18 were males and 21 were females, and the mean age was 5.9±14.4 (28-89) years. The most common primary site was oral cavity (12 cases), and followed by sino-nasal cavity (11 cases), parotid gland (5 cases), and etc. For treatment, 17 patients underwent surgery alone, 16 received surgery with postoperative radiation therapy, and 3 patients received radiation therapy only. Three patients refused any further treatments. Recurrence occurred in 15 patients. The most common site of recurrence was the lung. The mean time to recurrence was 31.7 months. The 5 and 10 years’ overall survival rate was 79.3% and 74%, respectively. The 2 and 5 years’ overall survival rate was 69.6% and 62.6% in patients with distant metastasis. Conclusion Distant metastasis is an important prognostic factor in adenoid cystic carcinoma, and eventually one third of patients have distant metastasis, especially in the lung. An appropriate treatment for lung metastasis is necessary because some patients with pulmonary metastasis survive for a quite long time. | - |
dc.publisher | 대한두경부종양학회 | - |
dc.title | Oncologic Outcome and Distant Metastasis of Head and Neck Adenoid Cystic Carcinoma | - |
dc.title.alternative | 두경부 선낭암종의 예후와 원격 전이 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 박혜진 | - |
dc.contributor.affiliatedAuthor | 송창면 | - |
dc.contributor.affiliatedAuthor | 지용배 | - |
dc.contributor.affiliatedAuthor | 태경 | - |
dc.identifier.bibliographicCitation | 대한두경부종양학회지, v.34, no.2, pp.23 - 28 | - |
dc.relation.isPartOf | 대한두경부종양학회지 | - |
dc.citation.title | 대한두경부종양학회지 | - |
dc.citation.volume | 34 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 23 | - |
dc.citation.endPage | 28 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Adenoid cystic carcinoma | - |
dc.subject.keywordAuthor | Salivary cancer | - |
dc.subject.keywordAuthor | Head and neck cancer | - |
dc.subject.keywordAuthor | Recurrence | - |
dc.subject.keywordAuthor | Distant metastasis | - |
dc.identifier.url | https://www.kjhno.org/journal/view.php?number=877 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.